{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pad:pad-015-statin-therapy",
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-06T06:00:00.000Z",
    "last_updated": "2026-01-06T06:00:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent",
      "quality-enhancement-agent"
    ],
    "confidence": 0.95,
    "status": "peer-reviewed",
    "copyright_compliance": "Original content based on general medical knowledge",
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/pad",
    "type": "pharmacotherapy",
    "difficulty": "intermediate",
    "importance": "critical",
    "aku_id": "PAD-015",
    "keywords": [
      "statin therapy",
      "PAD",
      "lipid management",
      "atorvastatin",
      "rosuvastatin",
      "cardiovascular prevention"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "lower_extremity_arterial_disease",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Statin Therapy in Peripheral Arterial Disease",
    "statement": "Statin Therapy in Peripheral Arterial Disease is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Pad that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Statin Therapy in Peripheral Arterial Disease helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Statin Therapy in Peripheral Arterial Disease include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Statin Therapy in Peripheral Arterial Disease."
    },
    "pharmacology": {
      "high_intensity_regimens": {
        "atorvastatin": "40-80 mg daily",
        "rosuvastatin": "20-40 mg daily",
        "ldl_reduction": ">50% from baseline"
      },
      "moderate_intensity_regimens": {
        "use": "Only if high-intensity not tolerated",
        "atorvastatin": "10-20 mg daily",
        "simvastatin": "20-40 mg daily",
        "rosuvastatin": "5-10 mg daily"
      },
      "pleiotropic_effects": [
        "Plaque stabilization and reduced rupture risk",
        "Anti-inflammatory (reduced hs-CRP)",
        "Improved endothelial function",
        "Reduced platelet aggregation",
        "Antioxidant properties"
      ]
    },
    "clinical_evidence": {
      "heart_protection_study": {
        "result": "22% reduction in major vascular events with simvastatin",
        "pad_subgroup": "Significant benefit in PAD patients"
      },
      "walking_improvement": {
        "mechanism": "Improved endothelial function and blood flow",
        "magnitude": "Modest improvement in claudication distance"
      },
      "limb_outcomes": {
        "male_reduction": "18-30% reduction in major adverse limb events",
        "graft_patency": "Improved patency after bypass surgery"
      }
    },
    "practical_considerations": {
      "monitoring": {
        "baseline": "Lipid panel, liver enzymes, creatine kinase",
        "follow_up": "Lipid panel at 4-12 weeks, then annually",
        "liver_enzymes": "Only if symptoms develop"
      },
      "adverse_effects": {
        "myalgias": "5-10%, often nocebo effect",
        "myopathy": "Rare, <0.1%",
        "rhabdomyolysis": "Very rare",
        "hepatotoxicity": "Rare, usually reversible"
      },
      "drug_interactions": [
        "CYP3A4 inhibitors increase atorvastatin/simvastatin levels",
        "Gemfibrozil increases myopathy risk",
        "Cyclosporine requires dose adjustment"
      ],
      "intolerance_management": [
        "Try alternative statin",
        "Reduce dose and uptitrate",
        "Alternate day dosing",
        "Consider ezetimibe or PCSK9 inhibitors"
      ]
    },
    "terminology": {
      "snomed_ct": "372912004",
      "icd_10": "Z79.899"
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Statin Therapy in PAD"
    },
    "altLabel": [
      "Lipid Management in PAD",
      "HMG-CoA Reductase Inhibitors in PAD"
    ],
    "definition": {
      "@language": "en",
      "@value": "High-intensity statin therapy for cardiovascular and limb protection in peripheral arterial disease patients."
    },
    "notation": "PAD-015"
  },
  "clinical_features": {
    "presentation": [
      "All PAD patients regardless of symptoms",
      "Pre- and post-revascularization",
      "Claudication and CLTI"
    ],
    "diagnosis": [
      "Baseline lipid panel",
      "Assess for contraindications",
      "Document prior statin use/intolerance"
    ],
    "treatment": [
      "High-intensity statin as first-line",
      "Target LDL <70 mg/dL",
      "Ezetimibe as add-on if needed",
      "PCSK9 inhibitors for refractory cases"
    ]
  },
  "relationships": {
    "prerequisites": [
      "vascular:pad:pad-013-risk-modification"
    ],
    "enables": [
      "vascular:pad:cardiovascular-prevention",
      "vascular:pad:limb-outcomes"
    ],
    "skos:broader": [
      "vascular:pad:pad-013-risk-modification"
    ],
    "skos:related": [
      "vascular:pad:antiplatelet-therapy",
      "vascular:pad:best-medical-therapy"
    ],
    "skos:narrower": [],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Statin_Therapy_in_Peripheral_Arterial_Disease"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). Statin Therapy in Peripheral Arterial Disease. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "internal medicine residents",
      "medical students"
    ],
    "estimated_time": "15min",
    "learning_objectives": [
      "Identify PAD as an automatic indication for high-intensity statin therapy",
      "Prescribe appropriate statin regimens for PAD patients",
      "Explain the pleiotropic benefits of statins beyond LDL lowering",
      "Manage statin intolerance in PAD patients"
    ],
    "clinical_pearls": [
      "PAD = automatic high-intensity statin indication regardless of LDL",
      "Atorvastatin 80mg or rosuvastatin 40mg is the target",
      "Statins improve walking distance and reduce MALE",
      "True statin myopathy is rare - consider nocebo effect",
      "Never stop statins perioperatively for vascular surgery"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codeValue": "372912004",
      "codingSystem": "SNOMED-CT",
      "name": "Statin therapy"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "Z79.899",
      "codingSystem": "ICD-10-CM",
      "name": "Long term use of other medication"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "E78.5",
      "codingSystem": "ICD-10-CM",
      "name": "Hyperlipidemia, unspecified"
    }
  ],
  "owl:sameAs": "http://dbpedia.org/resource/Statin_Therapy_in_Peripheral_Arterial_Disease",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}